长链非编码RNA在胶质瘤发生发展中的研究进展

doi:10.3969/j.issn.1673-8640.2026.08.016

摘要/Abstract

摘要：

胶质瘤是中枢神经系统最常见的恶性肿瘤，其高侵袭性等恶性特征常导致疗效不佳，患者预后较差。长链非编码RNA（lncRNA）在胶质瘤的发生、发展中承担关键角色。文章综述了lncRNA在胶质瘤增殖、侵袭、血管生成等恶性生物学行为中的分子机制，以及在胶质瘤辅助诊断和预后评估中的价值，以期为胶质瘤的辅助诊断、治疗和预后评估提供参考。

关键词: 长链非编码RNA, 胶质瘤, 生物标志物, 诊断, 预后评估

Abstract:

Glioma is the most common malignant tumor of the central nervous system，and its aggressive feature often leads to poor treatment outcomes and unfavorable patient prognosis. Long non-coding RNA（lncRNA） play a role in the initiation and progression of gliomas. This review summarizes the molecular mechanisms by which lncRNA regulates malignant biological behaviors such as proliferation，invasion and angiogenesis in gliomas，as well as their potential in auxiliary diagnosis and prognostic evaluation. The aim is to provide a reference for the auxiliary diagnosis，treatment and prognosis assessment of gliomas.

Key words: Long non-coding RNA, Glioma, Biomarker, Diagnosis, Prognostic evaluation

中图分类号:

R446.7

和一鸣, 王立康, 刘文庆, 张丽娜. 长链非编码RNA在胶质瘤发生发展中的研究进展[J]. 检验医学, 2026, 41(8): 818-823.

HE Yiming, WANG Likang, LIU Wenqing, ZHANG Lina. Research progress on long non-coding RNA in the development and progression of gliomas[J]. Laboratory Medicine, 2026, 41(8): 818-823.

图/表 1

参考文献 49

[1]	Horbinski C, Berger T, Packer R J, et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours[J]. Nat Rev Neurol, 2022, 18(9):515-529. DOI PMID
[2]	Ostrom Q T, Price M, Neff C, et al. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019[J]. Neuro Oncol, 2022, 24(Suppl 5):v1-v95.
[3]	Weller M, Wen P Y, Chang S M, et al. Glioma[J]. Nat Rev Dis Primers, 2024, 10(1):33. DOI PMID
[4]	Xu X, Liang Y, Gareev I, et al. LncRNA as potential biomarker and therapeutic target in glioma[J]. Mol Biol Rep, 2023, 50(1):841-851. DOI
[5]	Bridges M C, Daulagala A C, Kourtidis A. LNCcation:lncRNA localization and function[J]. J Cell Biol, 2021, 220(2):e202009045. DOI URL
[6]	Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs:mechanisms and disease relevance[J]. Nat Rev Mol Cell Biol, 2024, 25(5):396-415. DOI
[7]	Dai C, Qianjiang H, Fu R, et al. Epigenetic and epitranscriptomic role of lncRNA in carcinogenesis(review)[J]. Int J Oncol, 2025, 66(4):29.
[8]	Liu Y, Yuan H, Fan J, et al. The pathogenesis mechanism and potential clinical value of lncRNA in gliomas[J]. Discov Oncol, 2024, 15(1):266. DOI PMID
[9]	Pouyan A, Ghorbanlo M, Eslami M, et al. Glioblastoma multiforme:insights into pathogenesis,key signaling pathways,and therapeutic strategies[J]. Mol Cancer, 2025, 24(1):58. DOI
[10]	Lu Z, Chen J, Luo C. The m6A modification of LncRNA LINC00200 regulated by WTAP accelerates glioma tumorigenesis by regulating Wnt/β-catenin pathway[J]. Cell Div, 2025, 20(1):10. DOI PMID
[11]	黄琦, 翟海程. lncRNA CERS6-AS1通过调控miR-138-2-3p抑制人胶质瘤细胞系增殖[J]. 医学分子生物学杂志, 2023, 20(1):20-25.
[12]	张沁仇, 马力, 王朝霞. 长链非编码RNA SNHG20在恶性肿瘤中的研究进展[J]. 南京医科大学学报(自然科学版), 2024, 44(9):1283-1291.
[13]	崔创, 林涛, 束坤, 等. LncRNA MYU对胶质瘤细胞周期分布、增殖、转移和凋亡以及PI3K/Akt信号通路的影响[J]. 现代生物医学进展, 2024, 24(3):428-433.
[14]	Sun J, Wang L. HOXA-AS2 enhances GBM cell malignancy by suppressing miR-2116-3p thereby upregulating SERPINA3[J]. BMC Cancer, 2022, 22(1):366. DOI PMID
[15]	Khoshandam M, Sideris N, Ahmadieh-yazdi A, et al. The functional role of LncRNA HOXA-AS2 in multiple human cancers[J]. Pathol Res Pract, 2025, 266:155795. DOI URL
[16]	Zhang Y, Wang Y, Yang Y, et al. Long noncoding RNA SNHG4 promotes glioma progression via regulating miR-367-3p/MYO1B axis in zebrafish xenografts[J]. Hum Cell, 2025, 38(2):53. DOI PMID
[17]	Bora Yildiz C, Du J, Mohan K N, et al. The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma[J]. Epigenomics, 2025, 17(2):125-140. DOI PMID
[18]	Deforzh E, Uhlmann E J, Das E, et al. Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus,and neoplastic transformation in glioma[J]. Mol Cell, 2022, 82(10):1894-1908.e5. DOI PMID
[19]	Wong C H, Li C H, Man Tong J H, et al. The establishment of CDK9/RNA PolII/H3K4me3/DNA methylation feedback promotes HOTAIR expression by RNA elongation enhancement in cancer[J]. Mol Ther, 2022, 30(4):1597-1609. DOI PMID
[20]	Ahmad F, Sudesh R, Ahmed A T, et al. Roles of HOTAIR long non-coding RNA in gliomas and other CNS disorders[J]. Cell Mol Neurobiol, 2024, 44(1):23. DOI PMID
[21]	Wu X, Fu M, Ge C, et al. m6A-mediated upregulation of lncRNA CHASERR promotes the progression of glioma by modulating the miR-6893-3p/TRIM14 axis[J]. Mol Neurobiol, 2024, 61(8):5418-5440. DOI
[22]	Chen S, Tu S, Huang Y, et al. LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis[J]. Naunyn Schmiedebergs Arch Pharmacol, 2025, 398(6):6787-6799. DOI
[23]	Hanahan D, Weinberg R A. Hallmarks of cancer:the next generation[J]. Cell, 2011, 144(5):646-674. DOI URL
[24]	郑雯, 林岩. 长链非编码RNA与肿瘤血管生成的研究进展[J]. 临床肿瘤学杂志, 2022, 27(9):847-852.
[25]	Li D, Zhang Z, Xia C, et al. Non-coding RNAs in glioma microenvironment and angiogenesis[J]. Front Mol Neurosci, 2021, 14:763610. DOI URL
[26]	Hu M, Gu W, Huai Y, et al. Mechanism of lncRNA WARS2-IT1 promoting angiogenesis of glioma through miR-299-3P/VEGFA axis and activating PI3K/AKT signaling pathway[J]. Cytotechnology, 2025, 77(4):157. DOI PMID
[27]	Zhao H, Wang Y, Liang C, et al. LncRNA FOXD3-AS1/miR-128-3p axis-mediated IGF2BP3 in glioma stimulates cancer angiogenesis and progression[J]. Folia Neuropathol, 2023, 61(2):168-184. DOI PMID
[28]	Kang C M, Zhao J J, Yuan Y S, et al. Long noncoding RNA RP11-732M18.3 promotes glioma angiogenesis by upregulating VEGFA[J]. Front Oncol, 2022, 12:873037. DOI URL
[29]	Amer R G, Ezz El Arab L R, Abd El Ghany D, et al. Prognostic utility of lncRNAs(LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme(GBM)[J]. J Neurooncol, 2022, 158(3):435-444. DOI
[30]	Yuan Q, Gao C, Lai X D, et al. Analysis of long noncoding RNA ZNF667-AS1 as a potential biomarker for diagnosis and prognosis of glioma patients[J]. Dis Markers, 2020, 2020:8895968.
[31]	Tan S K, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme[J]. Mol Cancer, 2018, 17(1):74. DOI PMID
[32]	张珂珂, 张振, 郭庚寅, 等. LncRNA MEG3在胶质瘤组织中的表达变化及其相关功能[J]. 山东医药, 2023, 63(4):11-16.
[33]	Shi F, Hu J, Zheng P, et al. LncRNA PANTR1 is associated with poor prognostic and suppresses apoptosis in glioma[J]. J Oncol, 2023, 2023:8537036.
[34]	Sun Y, Jing Y, Zhang Y. Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis[J]. World J Surg Oncol, 2021, 19(1):287. DOI PMID
[35]	Qiu Q, Ding X, Chen J, et al. Nanobiotechnology-based treatment strategies for malignant relapsed glioma[J]. J Control Release, 2023, 358:681-705. DOI URL
[36]	Louis D N, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system:a summary[J]. Neuro Oncol, 2021, 23(8):1231-1251. DOI URL
[37]	Wu X, Yang L, Wang J, et al. The involvement of long non-coding RNAs in glioma:from early detection to immunotherapy[J]. Front Immunol, 2022, 13:897754. DOI URL
[38]	Wang J, Chen Y, Wang Q, et al. LncRNA SPRY4-IT1 facilitates cell proliferation and angiogenesis of glioma via the miR-101-3p/EZH2/VEGFA signaling axis[J]. Cancer Med, 2023, 12(6):7309-7326. DOI URL
[39]	You A, Gu J, Wang J, et al. Value of long non-coding RNA HAS2-AS1 as a diagnostic and prognostic marker of glioma[J]. Neurologia(Engl Ed), 2024, 39(4):353-360.
[40]	Zhao S, Liu M, Zhou H. Exploring the multifaceted role of key lncRNA in glioma:from genetic expression to clinical implications and immunotherapy potential[J]. Heliyon, 2024, 10(17):e36822. DOI URL
[41]	Pan Y B, Zhu Y, Zhang Q W, et al. Prognostic and predictive value of a long non-coding RNA signature in glioma:a lncRNA expression analysis[J]. Front Oncol, 2020, 10:1057. DOI URL
[42]	Wu Y, Li F, Yang C, et al. Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma[J]. Sci Rep, 2025, 15(1):954. DOI
[43]	Sun L, Yang Z, Chen H, et al. Long non-coding RNA CRNDE promotes the development of glioma by inducing polarization of M2-type macrophages[J]. Mol Neurobiol, 2025, 62(9):11769-11783. DOI PMID
[44]	Ji Y L, Kang K, Lv Q L, et al. Roles of lncRNA-MALAT1 in the progression and prognosis of gliomas[J]. Mini Rev Med Chem, 2024, 24(8):786-792. DOI URL
[45]	E Y, Zhang X, Ma H, et al. Long non-coding RNA prader willi/angelman region RNA 6 suppresses glioma development by modulating microRNA-106a-5p[J]. Biochem Genet, 2024, 62(2):1365-1378. DOI
[46]	Wang H Y, Xie Y, Du H, et al. High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration[J]. Peer J, 2023, 11:e16104. DOI URL
[47]	Zhang B, Cheng Y, Li R, et al. Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme[J]. Transl Cancer Res, 2023, 12(1):13-30. DOI PMID
[48]	Lin P, He L, Tian N, et al. The evaluation of six genes combined value in glioma diagnosis and prognosis[J]. J Cancer Res Clin Oncol, 2023, 149(13):12413-12433. DOI PMID
[49]	He Y, Ye Y, Tian W, et al. A novel lncRNA panel related to ferroptosis,tumor progression,and microenvironment is a robust prognostic indicator for glioma patients[J]. Front Cell Dev Biol, 2021, 9:788451. DOI URL

lncRNA	表达趋势	组织样本量	在预后评估中的作用	统计值	临床用途	参考文献
SLCO4A1-AS1	高表达	未明确指出	SLCO4A1-AS1高表达是胶质瘤患者OS缩短的独立危险因素	HR^①=1.785，95%CI为1.322~2.410，P<0.001	潜在预后标志物	[42]
CRNDE	高表达	42例不同级别胶质瘤样本（Ⅰ~Ⅱ级10例，Ⅲ~Ⅳ级32例）	高表达lncRNA CRNDE的多形性胶质母细胞瘤、低级别胶质瘤患者OS较短		潜在预后标志物	[43]
MKLN1-AS	高表达	48 例胶质瘤组织样本（Ⅰ~Ⅱ级30例，Ⅲ~Ⅳ级18例）	MKLN1-AS高表达者OS较短		潜在预后标志物	[22]
CHASERR	高表达	58例胶质瘤样本	高表达lncRNA CHASERR的胶质瘤患者总体生存率较低		潜在预后标志物	[21]
MALAT1	高表达	106例胶质瘤样本	高表达lncRNA MALAT1的胶质瘤患者总体生存率较低	HR= 2.32，95%CI为1.64~3.27，P<0.001	预后标志物	[44]
PWAR6	低表达	105例胶质瘤样本	PWAR6低表达与较低的生存率存在显著关联	HR=2.004，95% CI为1.081~3.714，P=0.027	预后标志物	[45]
LYRM4 - AS1	高表达	290例胶质瘤样本， 11例正常组织样本	LYRM4-AS1高表达者OS、疾病特异性生存期和无进展生存期均较短		预后标志物	[46]

lncRNA	表达趋势	组织样本量	在预后评估中的作用	统计值	临床用途	参考文献
SLCO4A1-AS1	高表达	未明确指出	SLCO4A1-AS1高表达是胶质瘤患者OS缩短的独立危险因素	HR^①=1.785，95%CI为1.322~2.410，P<0.001	潜在预后标志物	[42]
CRNDE	高表达	42例不同级别胶质瘤样本（Ⅰ~Ⅱ级10例，Ⅲ~Ⅳ级32例）	高表达lncRNA CRNDE的多形性胶质母细胞瘤、低级别胶质瘤患者OS较短		潜在预后标志物	[43]
MKLN1-AS	高表达	48 例胶质瘤组织样本（Ⅰ~Ⅱ级30例，Ⅲ~Ⅳ级18例）	MKLN1-AS高表达者OS较短		潜在预后标志物	[22]
CHASERR	高表达	58例胶质瘤样本	高表达lncRNA CHASERR的胶质瘤患者总体生存率较低		潜在预后标志物	[21]
MALAT1	高表达	106例胶质瘤样本	高表达lncRNA MALAT1的胶质瘤患者总体生存率较低	HR= 2.32，95%CI为1.64~3.27，P<0.001	预后标志物	[44]
PWAR6	低表达	105例胶质瘤样本	PWAR6低表达与较低的生存率存在显著关联	HR=2.004，95% CI为1.081~3.714，P=0.027	预后标志物	[45]
LYRM4 - AS1	高表达	290例胶质瘤样本， 11例正常组织样本	LYRM4-AS1高表达者OS、疾病特异性生存期和无进展生存期均较短		预后标志物	[46]